Research programme: dexamethasone ophthalmic - Novagali Pharma

Drug Profile

Research programme: dexamethasone ophthalmic - Novagali Pharma

Alternative Names: Nova 22026

Latest Information Update: 22 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novagali Pharma
  • Class Anti-inflammatories; Antiemetics; Antineoplastics; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Ocular inflammation

Most Recent Events

  • 22 Jan 2008 Discontinued - Preclinical for Ocular inflammation in France (Ophthalmic)
  • 25 Oct 2006 Preclinical trials in Ocular inflammation in France (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top